Literature DB >> 28541680

Regulatory Mechanisms and Novel Therapeutic Targeting Strategies for Protein Tyrosine Phosphatases.

Zhi-Hong Yu1, Zhong-Yin Zhang1.   

Abstract

An appropriate level of protein phosphorylation on tyrosine is essential for cells to react to extracellular stimuli and maintain cellular homeostasis. Faulty operation of signal pathways mediated by protein tyrosine phosphorylation causes numerous human diseases, which presents enormous opportunities for therapeutic intervention. While the importance of protein tyrosine kinases in orchestrating the tyrosine phosphorylation networks and in target-based drug discovery has long been recognized, the significance of protein tyrosine phosphatases (PTPs) in cellular signaling and disease biology has historically been underappreciated, due to a large extent to an erroneous assumption that they are largely constitutive and housekeeping enzymes. Here, we provide a comprehensive examination of a number of regulatory mechanisms, including redox modulation, allosteric regulation, and protein oligomerization, that control PTP activity. These regulatory mechanisms are integral to the myriad PTP-mediated biochemical events and reinforce the concept that PTPs are indispensable and specific modulators of cellular signaling. We also discuss how disruption of these PTP regulatory mechanisms can cause human diseases and how these diverse regulatory mechanisms can be exploited for novel therapeutic development.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28541680      PMCID: PMC5812791          DOI: 10.1021/acs.chemrev.7b00105

Source DB:  PubMed          Journal:  Chem Rev        ISSN: 0009-2665            Impact factor:   60.622


  279 in total

Review 1.  The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling.

Authors:  Benjamin G Neel; Haihua Gu; Lily Pao
Journal:  Trends Biochem Sci       Date:  2003-06       Impact factor: 13.807

2.  Dimeric quaternary structure of the prototypical dual specificity phosphatase VH1.

Authors:  Adem C Koksal; Jonathan D Nardozzi; Gino Cingolani
Journal:  J Biol Chem       Date:  2009-02-10       Impact factor: 5.157

Review 3.  From promiscuity to precision: protein phosphatases get a makeover.

Authors:  David M Virshup; Shirish Shenolikar
Journal:  Mol Cell       Date:  2009-03-13       Impact factor: 17.970

Review 4.  Regulation of protein tyrosine phosphatases by reversible oxidation.

Authors:  Arne Ostman; Jeroen Frijhoff; Asa Sandin; Frank-D Böhmer
Journal:  J Biochem       Date:  2011-08-19       Impact factor: 3.387

5.  Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis.

Authors:  Gordon Chan; Demetrios Kalaitzidis; Tatiana Usenko; Jeffery L Kutok; Wentian Yang; M Golam Mohi; Benjamin G Neel
Journal:  Blood       Date:  2009-01-29       Impact factor: 22.113

6.  The Cys(X)5Arg catalytic motif in phosphoester hydrolysis.

Authors:  Z Y Zhang; Y Wang; L Wu; E B Fauman; J A Stuckey; H L Schubert; M A Saper; J E Dixon
Journal:  Biochemistry       Date:  1994-12-27       Impact factor: 3.162

7.  Expression of PRL-3 phosphatase in human gastric carcinomas: close correlation with invasion and metastasis.

Authors:  Upik Anderiani Miskad; Shuho Semba; Hirotaka Kato; Hiroshi Yokozaki
Journal:  Pathobiology       Date:  2004       Impact factor: 4.342

8.  Activation of the SH2-containing protein tyrosine phosphatase, SH-PTP2, by phosphotyrosine-containing peptides derived from insulin receptor substrate-1.

Authors:  S Sugimoto; T J Wandless; S E Shoelson; B G Neel; C T Walsh
Journal:  J Biol Chem       Date:  1994-05-06       Impact factor: 5.157

9.  Prognostic significance of phosphatase of regenerating liver-3 expression in ovarian cancer.

Authors:  Tingting Ren; Beihai Jiang; Xiaofang Xing; Bin Dong; Lirong Peng; Lin Meng; Huiyu Xu; Chengchao Shou
Journal:  Pathol Oncol Res       Date:  2009-02-27       Impact factor: 3.201

10.  Oncogenic function and prognostic significance of protein tyrosine phosphatase PRL-1 in hepatocellular carcinoma.

Authors:  Shaowen Jin; Kaimei Wang; Kang Xu; Junyao Xu; Jian Sun; Zhonghua Chu; Dechen Lin; Phillip H Koeffler; Jie Wang; Dong Yin
Journal:  Oncotarget       Date:  2014-06-15
View more
  26 in total

1.  RNA Sequencing of Carboplatin- and Paclitaxel-Resistant Endometrial Cancer Cells Reveals New Stratification Markers and Molecular Targets for Cancer Treatment.

Authors:  Raffaele Hellweg; Ashley Mooneyham; Zenas Chang; Mihir Shetty; Edith Emmings; Yoshie Iizuka; Christopher Clark; Timothy Starr; Juan H Abrahante; Florian Schütz; Gottfried Konecny; Peter Argenta; Martina Bazzaro
Journal:  Horm Cancer       Date:  2018-06-27       Impact factor: 3.869

2.  Mechanism of thienopyridone and iminothienopyridinedione inhibition of protein phosphatases.

Authors:  Zhidian Zhang; Guennadi Kozlov; Yu Seby Chen; Kalle Gehring
Journal:  Medchemcomm       Date:  2019-04-05       Impact factor: 3.597

3.  PRL3 pseudophosphatase activity is necessary and sufficient to promote metastatic growth.

Authors:  Guennadi Kozlov; Yosuke Funato; Yu Seby Chen; Zhidian Zhang; Katalin Illes; Hiroaki Miki; Kalle Gehring
Journal:  J Biol Chem       Date:  2020-06-22       Impact factor: 5.157

Review 4.  Functional interrogation and therapeutic targeting of protein tyrosine phosphatases.

Authors:  Aaron D Krabill; Zhong-Yin Zhang
Journal:  Biochem Soc Trans       Date:  2021-08-27       Impact factor: 5.407

5.  Structure-activity studies of PTPRD phosphatase inhibitors identify a 7-cyclopentymethoxy illudalic acid analog candidate for development.

Authors:  Ian M Henderson; Fanxun Zeng; Nazmul H Bhuiyan; Dan Luo; Maria Martinez; Jane Smoake; Fangchao Bi; Chamani Perera; David Johnson; Thomas E Prisinzano; Wei Wang; George R Uhl
Journal:  Biochem Pharmacol       Date:  2021-12-02       Impact factor: 6.100

6.  Mechanistic insights explain the transforming potential of the T507K substitution in the protein-tyrosine phosphatase SHP2.

Authors:  Ruo-Yu Zhang; Zhi-Hong Yu; Lan Chen; Chad D Walls; Sheng Zhang; Li Wu; Zhong-Yin Zhang
Journal:  J Biol Chem       Date:  2020-03-18       Impact factor: 5.157

7.  Structure of the Complex of an Iminopyridinedione Protein Tyrosine Phosphatase 4A3 Phosphatase Inhibitor with Human Serum Albumin.

Authors:  Mateusz P Czub; Adam M Boulton; Ettore J Rastelli; Nikhil R Tasker; Taber S Maskrey; Isabella K Blanco; Kelley E McQueeney; John H Bushweller; Wladek Minor; Peter Wipf; Elizabeth R Sharlow; John S Lazo
Journal:  Mol Pharmacol       Date:  2020-09-25       Impact factor: 4.436

8.  Computational Strategy for Bound State Structure Prediction in Structure-Based Virtual Screening: A Case Study of Protein Tyrosine Phosphatase Receptor Type O Inhibitors.

Authors:  Xuben Hou; David Rooklin; Duxiao Yang; Xiao Liang; Kangshuai Li; Jianing Lu; Cheng Wang; Peng Xiao; Yingkai Zhang; Jin-Peng Sun; Hao Fang
Journal:  J Chem Inf Model       Date:  2018-10-19       Impact factor: 4.956

9.  A cellular target engagement assay for the characterization of SHP2 (PTPN11) phosphatase inhibitors.

Authors:  Celeste Romero; Lester J Lambert; Douglas J Sheffler; Laurent J S De Backer; Dhanya Raveendra-Panickar; Maria Celeridad; Stefan Grotegut; Socorro Rodiles; John Holleran; Eduard Sergienko; Elena B Pasquale; Nicholas D P Cosford; Lutz Tautz
Journal:  J Biol Chem       Date:  2020-01-17       Impact factor: 5.157

10.  PTP-MEG2 regulates quantal size and fusion pore opening through two distinct structural bases and substrates.

Authors:  Yun-Fei Xu; Xu Chen; Zhao Yang; Peng Xiao; Chun-Hua Liu; Kang-Shuai Li; Xiao-Zhen Yang; Yi-Jing Wang; Zhong-Liang Zhu; Zhi-Gang Xu; Sheng Zhang; Chuan Wang; You-Chen Song; Wei-Dong Zhao; Chang-He Wang; Zhi-Liang Ji; Zhong-Yin Zhang; Min Cui; Jin-Peng Sun; Xiao Yu
Journal:  EMBO Rep       Date:  2021-03-25       Impact factor: 8.807

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.